Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04719273 · ClinicalTrials.gov registry record · Phase 2
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
A Phase 2 study of Refractory Endometrial Carcinoma and Refractory Endometrial Endometrioid Adenocarcinoma, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT04719273 is a Phase 2 study of Refractory Endometrial Carcinoma and Refractory Endometrial Endometrioid Adenocarcinoma that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 14 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT04719273, a Phase 2 study of Refractory Endometrial Carcinoma and Refractory Endometrial Endometrioid Adenocarcinoma, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use of progesterone by the tumor cells. Anastrozole is a drug that blocks the production of estrogen in the body. Giving onapristone with anastrozole may work better than anastrozole alone in treating patients with hormone receptor positive endometrial cancer.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DRUG Anastrozole
- DRUG Extended-release Onapristone
- DIAGNOSTIC_TEST Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)
Study Locations (2)
Pennsylvania
- Jefferson Abington Hospital - Abington
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04719273
The ClinicalTrials.gov registry entry for NCT04719273 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Refractory Endometrial Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04719273 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04719273 about?
NCT04719273 is a clinical study titled "Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer". This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapri...
What is the current status of trial NCT04719273?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2021-01-28. Estimated completion is 2025-12-31.
What conditions does trial NCT04719273 study?
This clinical trial studies the following conditions: Refractory Endometrial Carcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Adenocarcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma.
What interventions are being tested in trial NCT04719273?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Anastrozole (DRUG), Extended-release Onapristone (DRUG), Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04719273?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04719273 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Refractory Endometrial Carcinoma
All registered trials for this condition
Refractory Endometrial Endometrioid Adenocarcinoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.